In adults with osteogenesis imperfecta, teriparatide followed by zoledronic acid did not significantly reduce incident fractures versus standard care.
In plain wordsIn adults with osteogenesis imperfecta, teriparatide followed by zoledronic acid did not significantly reduce fractures compared with standard care.
- Peptide
- Teriparatide (PTH 1-34)
- Outcome
- No significant changeIncident fractures
- Study
n = 349
- Comparator
- Standard care
- Analysis
- Primary
- Outcome group
- Bone and joint · Musculoskeletal
Measurements
- Incident fracture rate
- 36.9%
- teriparatide plus zoledronic acid
- Incident fracture rate
- 36.4%
- standard care
- Hazard ratio
- 0.97 ratio
- versus standard care
Source sentences
In the teriparatide plus zoledronic acid group 65 of 176 (36.9%) had incident fractures compared with 63 of 173 (36.4%) in the standard care group (absolute risk reduction, -1.57%; 95% CI, -9.90% to 5.89%; hazard ratio, 0.97; 95% CI, 0.68 to 1.38).
3 context sentences(design, population, supporting numbers)
Multicenter open-label, parallel-group, randomized clinical trial, conducted between May 17, 2017, and March 21, 2025, in adults attending one of 27 referral centers with a clinical diagnosis of osteogenesis imperfecta.
Those in the active group received 20 μg of teriparatide daily by subcutaneous injection for 2 years followed by an infusion of 5 mg of zoledronic acid.
In the standard care group, bisphosphonates and other bone-targeted medicines could be used but teriparatide and other bone anabolic drugs were prohibited.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).